{"transactions":[{"id":727725,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-24T22:06:17.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":5277,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date."}],"balance_after":5277,"derivative":{"exercise_price":68.92,"expiration_date":"2036-06-21","underlying":"Common Stock","underlying_shares":5277},"source":{"system":"sec-edgar","filing":"0001470831-26-000634","document":"wk-form4_1782338774.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000634/wk-form4_1782338774.xml","form_type":"4"}},{"id":727724,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-24T22:06:17.000Z","date":"2026-06-22","kind":"grant","planned":false,"acquired":true,"shares":3990,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":18079,"source":{"system":"sec-edgar","filing":"0001470831-26-000634","document":"wk-form4_1782338774.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083126000634/wk-form4_1782338774.xml","form_type":"4"}},{"id":993889,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-19T22:08:19.000Z","date":"2025-11-18","kind":"sale","planned":false,"acquired":false,"shares":30993,"price":66.049,"value":2047056.657,"ownership":{"direct":false,"nature":"By Andrew W. Lo and Nancy N. Lo JTWROS"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sale price of the shares sold from $65.58 to $66.52 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."}],"balance_after":50583,"source":{"system":"sec-edgar","filing":"0001470831-25-000357","document":"wk-form4_1763590095.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083125000357/wk-form4_1763590095.xml","form_type":"4"}},{"id":993888,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-19T22:08:19.000Z","date":"2025-11-18","kind":"sale","planned":false,"acquired":false,"shares":24007,"price":65.2315,"value":1566012.6205,"ownership":{"direct":false,"nature":"By Andrew W. Lo and Nancy N. Lo JTWROS"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price of the shares sold from $64.58 to $65.56 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."}],"balance_after":81576,"source":{"system":"sec-edgar","filing":"0001470831-25-000357","document":"wk-form4_1763590095.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083125000357/wk-form4_1763590095.xml","form_type":"4"}},{"id":993887,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-19T22:08:19.000Z","date":"2025-11-17","kind":"sale","planned":false,"acquired":false,"shares":3798,"price":67.056,"value":254678.688,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price of the shares sold from $66.975 to $67.20 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."}],"balance_after":14089,"source":{"system":"sec-edgar","filing":"0001470831-25-000357","document":"wk-form4_1763590095.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083125000357/wk-form4_1763590095.xml","form_type":"4"}},{"id":993886,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-19T22:08:19.000Z","date":"2025-11-17","kind":"sale","planned":false,"acquired":false,"shares":36801,"price":66.6263,"value":2451914.4663,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sale price of the shares sold from $65.975 to $66.97 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."}],"balance_after":17887,"source":{"system":"sec-edgar","filing":"0001470831-25-000357","document":"wk-form4_1763590095.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000147083125000357/wk-form4_1763590095.xml","form_type":"4"}},{"id":1102698,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-24T23:13:23.000Z","date":"2025-06-20","kind":"grant","planned":false,"acquired":true,"shares":8425,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors."}],"balance_after":8425,"derivative":{"exercise_price":41.73,"expiration_date":"2035-06-19","underlying":"Common Stock","underlying_shares":8425},"source":{"system":"sec-edgar","filing":"0000950170-25-089674","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000095017025089674/ownership.xml","form_type":"4"}},{"id":1102697,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-24T23:13:23.000Z","date":"2025-06-20","kind":"grant","planned":false,"acquired":true,"shares":6589,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan.  One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":54688,"source":{"system":"sec-edgar","filing":"0000950170-25-089674","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000095017025089674/ownership.xml","form_type":"4"}},{"id":1109402,"issuer":{"id":4118,"kind":"organization","name":"AbCellera Biologics Inc."},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share option (right to buy)","published_at":"2025-06-16T21:30:33.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":238864,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to such option vest and become exercisable at the 2026 Annual General Meeting, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":541354,"derivative":{"exercise_price":3.15,"exercise_date":"2026-06-11","expiration_date":"2035-06-12","underlying":"Common Shares","underlying_shares":238864},"source":{"system":"sec-edgar","filing":"0001628280-25-031646","document":"wk-form4_1750109427.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679076/000162828025031646/wk-form4_1750109427.xml","form_type":"4"}},{"id":1157426,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-06T20:42:23.000Z","date":"2025-05-02","kind":"sale","planned":false,"acquired":false,"shares":100000,"price":38.499,"value":3849900.0,"ownership":{"direct":false,"nature":"By Andrew W. Lo and Nancy N. Lo JTWROS"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sale price of the shares sold from $38.155 to $38.75 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote."}],"balance_after":105583,"source":{"system":"sec-edgar","filing":"0000950170-25-064558","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000095017025064558/ownership.xml","form_type":"4"}},{"id":1469557,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-25T21:38:34.000Z","date":"2024-06-21","kind":"grant","planned":false,"acquired":true,"shares":26014,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the shares underlying the stock option will vest each year after June 21, 2024, such that all of the underlying shares will be vested on June 21, 2027, subject to the Reporting Person's continued service on the board of directors of the Issuer."}],"balance_after":26014,"derivative":{"exercise_price":27.36,"expiration_date":"2034-06-20","underlying":"Common Stock","underlying_shares":26014},"source":{"system":"sec-edgar","filing":"0000950170-24-077446","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000095017024077446/ownership.xml","form_type":"4"}},{"id":1470288,"issuer":{"id":4118,"kind":"organization","name":"AbCellera Biologics Inc."},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share option (right to buy)","published_at":"2024-06-24T22:19:57.000Z","date":"2024-06-21","kind":"grant","planned":false,"acquired":true,"shares":163934,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":302490,"derivative":{"exercise_price":2.94,"exercise_date":"2025-06-12","expiration_date":"2034-06-21","underlying":"Common Shares","underlying_shares":163934},"source":{"system":"sec-edgar","filing":"0001628280-24-029668","document":"wk-form4_1719267587.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679076/000162828024029668/wk-form4_1719267587.xml","form_type":"4"}},{"id":1845284,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-23T20:21:22.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":51501,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company."}],"balance_after":51501,"derivative":{"exercise_price":16.75,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":51501},"source":{"system":"sec-edgar","filing":"0001209191-23-039385","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000120919123039385/doc4.xml","form_type":"4"}},{"id":2095501,"issuer":{"id":4118,"kind":"organization","name":"AbCellera Biologics Inc."},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2022-12-05T17:34:41.000Z","date":"2022-12-01","kind":"grant","acquired":true,"shares":47231,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":138556,"derivative":{"exercise_price":13.18,"exercise_date":"2024-06-15","expiration_date":"2032-12-01","underlying":"Common Shares","underlying_shares":47231},"source":{"system":"sec-edgar","filing":"0001209191-22-059580","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679076/000120919122059580/doc4.xml","form_type":"4"}},{"id":2155689,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2022-09-20T01:53:32.000Z","date":"2022-09-15","kind":"grant","acquired":true,"shares":71850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Reflects an annual award of stock options to purchase Common Shares granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy. The award of stock options is scheduled to vest and become exercisable 100% on September 15, 2023, subject generally to the reporting person's continuous service through such date."}],"balance_after":71850,"derivative":{"exercise_price":3.5,"expiration_date":"2032-09-14","underlying":"Common Shares","underlying_shares":71850},"source":{"system":"sec-edgar","filing":"0001140361-22-033876","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036122033876/form4.xml","form_type":"4"}},{"id":2155688,"issuer":{"id":3185,"kind":"organization","name":"Roivant Sciences Ltd.","symbol":"ROIV"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":true}}],"security":"Common Shares","published_at":"2022-09-20T01:53:32.000Z","date":"2022-09-15","kind":"grant","acquired":true,"shares":52142,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects an annual award of restricted stock units with respect to Common Shares (\"RSUs\") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy.  The award of RSUs is scheduled to vest 100% on September 15, 2023, subject generally to the reporting person's continuous service through such date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects an annual award of restricted stock units with respect to Common Shares (\"RSUs\") granted pursuant to the Company's 2021 Equity Incentive Plan and the Company's Non-Employee Director Compensation Policy.  The award of RSUs is scheduled to vest 100% on September 15, 2023, subject generally to the reporting person's continuous service through such date."}],"balance_after":52142,"source":{"system":"sec-edgar","filing":"0001140361-22-033876","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036122033876/form4.xml","form_type":"4"}},{"id":2222112,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-24T20:31:58.000Z","date":"2022-06-22","kind":"grant","acquired":true,"shares":104921,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company."}],"balance_after":104921,"derivative":{"exercise_price":8.45,"expiration_date":"2032-06-22","underlying":"Common Stock","underlying_shares":104921},"source":{"system":"sec-edgar","filing":"0001209191-22-039256","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000120919122039256/doc4.xml","form_type":"4"}},{"id":2454430,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-04T00:57:06.000Z","date":"2021-12-30","kind":"purchase","acquired":true,"shares":1500,"price":14.3,"value":21450.0,"ownership":{"direct":true},"balance_after":48099,"source":{"system":"sec-edgar","filing":"0000899243-22-000188","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924322000188/doc4.xml","form_type":"4"}},{"id":2454429,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-04T00:57:06.000Z","date":"2021-12-29","kind":"purchase","acquired":true,"shares":6000,"price":12.9,"value":77400.0,"ownership":{"direct":true},"balance_after":46599,"source":{"system":"sec-edgar","filing":"0000899243-22-000188","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924322000188/doc4.xml","form_type":"4"}},{"id":2476729,"issuer":{"id":4118,"kind":"organization","name":"AbCellera Biologics Inc."},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2021-12-10T19:36:29.000Z","date":"2021-12-03","kind":"grant","acquired":true,"shares":91325,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The original option award was listed as 86,938 which is an administrative error due to an incorrect the Black-Scholes calculation. The correct number of awarded options is 91,325."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to such option vest and become exercisable annually in substantially equal installments over a three-year period, with the first tranche vested on December 3, 2022, subject to the Reporting Person's continuous service to the Issuer on each such date"}],"balance_after":91325,"derivative":{"exercise_price":14.02,"expiration_date":"2031-12-03","underlying":"Common Shares","underlying_shares":91325},"source":{"system":"sec-edgar","filing":"0001209191-21-068976","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679076/000120919121068976/doc4a.xml","form_type":"4/A","original_submission_date":"2021-12-07"}},{"id":2481679,"issuer":{"id":4118,"kind":"organization","name":"AbCellera Biologics Inc."},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (right to buy)","published_at":"2021-12-07T20:17:31.000Z","date":"2021-12-03","kind":"purchase","acquired":true,"shares":86938,"price":14.02,"value":1218870.76,"ownership":{"direct":true},"balance_after":86938,"source":{"system":"sec-edgar","filing":"0001209191-21-068291","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679076/000120919121068291/doc4.xml","form_type":"4"}},{"id":2658959,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-22T23:38:17.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":38895,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable in three annual installments after June 17, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date."}],"balance_after":38895,"derivative":{"exercise_price":62.63,"expiration_date":"2031-06-16","underlying":"Common Stock","underlying_shares":38895},"source":{"system":"sec-edgar","filing":"0000899243-21-025410","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924321025410/doc4.xml","form_type":"4"}},{"id":3099866,"issuer":{"id":3360,"kind":"organization","name":"BridgeBio Pharma, Inc.","symbol":"BBIO"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-25T20:38:16.000Z","date":"2020-06-23","kind":"grant","acquired":true,"shares":101223,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option vest and become exercisable in three annual installments after June 23, 2020, subject to the Reporting Person's continued service to the Issuer through each such vesting date."}],"balance_after":101223,"derivative":{"exercise_price":32.62,"expiration_date":"2030-06-22","underlying":"Common Stock","underlying_shares":101223},"source":{"system":"sec-edgar","filing":"0000899243-20-017663","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743881/000089924320017663/doc4.xml","form_type":"4"}},{"id":3483620,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-06-19T22:20:29.000Z","date":"2019-06-19","kind":"purchase","acquired":true,"shares":4957,"price":8.1693,"value":40495.2201,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made by Roivant Sciences Ltd. (\"Roivant\") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. The purchases were made by Roivant and not by the reporting person. See footnotes 3 and 4 for information on the reporting person's ownership via Roivant of the purchased Common Shares."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.00 to $8.27, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These Common Shares are directly beneficially owned by Roivant and indirectly beneficially owned by the reporting person. Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an \"Independent Director\" and collectively the \"Independent Directors\"), dispositions of the Common Shares require the approval of a majority of Roivant's board of directors, including (i) at least two Independent Directors, or, (ii) if there is only one independent director, that sole Independent Director. The reporting person is an Independent Director of Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"As the approval of the reporting person as an Independent Director, and, to the extent one other Independent Director is serving, that other Independent Director, is needed for Roivant to dispose of the Common Shares, the reporting person may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Common Shares directly beneficially owned by Roivant. The reporting person disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his respective pecuniary interest therein. Additionally, this filing shall not be deemed an admission that the reporting person and any other Independent Director constitute a \"group\" for purposes of Section 13(d) or Section 13(g) of the Securities Exchange Act of 1934, as amended."}],"balance_after":22860013,"source":{"system":"sec-edgar","filing":"0001104659-19-036418","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1679076/000110465919036418/a4.xml","form_type":"4"}},{"id":3483619,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-06-19T22:20:29.000Z","date":"2019-06-18","kind":"purchase","acquired":true,"shares":6706,"price":8.2107,"value":55060.9542,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made by Roivant Sciences Ltd. (\"Roivant\") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. The purchases were made by Roivant and not by the reporting person. See footnotes 3 and 4 for information on the reporting person's ownership via Roivant of the purchased Common Shares."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.09 to $8.29, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These Common Shares are directly beneficially owned by Roivant and indirectly beneficially owned by the reporting person. Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an \"Independent Director\" and collectively the \"Independent Directors\"), dispositions of the Common Shares require the approval of a majority of Roivant's board of directors, including (i) at least two Independent Directors, or, (ii) if there is only one independent director, that sole Independent Director. The reporting person is an Independent Director of Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"As the approval of the reporting person as an Independent Director, and, to the extent one other Independent Director is serving, that other Independent Director, is needed for Roivant to dispose of the Common Shares, the reporting person may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Common Shares directly beneficially owned by Roivant. The reporting person disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his respective pecuniary interest therein. Additionally, this filing shall not be deemed an admission that the reporting person and any other Independent Director constitute a \"group\" for purposes of Section 13(d) or Section 13(g) of the Securities Exchange Act of 1934, as amended."}],"balance_after":22855056,"source":{"system":"sec-edgar","filing":"0001104659-19-036418","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1679076/000110465919036418/a4.xml","form_type":"4"}},{"id":3483618,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-06-19T22:20:29.000Z","date":"2019-06-17","kind":"purchase","acquired":true,"shares":6541,"price":8.5346,"value":55824.8186,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made by Roivant Sciences Ltd. (\"Roivant\") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. The purchases were made by Roivant and not by the reporting person. See footnotes 3 and 4 for information on the reporting person's ownership via Roivant of the purchased Common Shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.11 to $8.70, inclusive. The reporting person undertakes to provide to Urovant Sciences Ltd. (\"Urovant\"), any security holder of Urovant, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These Common Shares are directly beneficially owned by Roivant and indirectly beneficially owned by the reporting person. Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an \"Independent Director\" and collectively the \"Independent Directors\"), dispositions of the Common Shares require the approval of a majority of Roivant's board of directors, including (i) at least two Independent Directors, or, (ii) if there is only one independent director, that sole Independent Director. The reporting person is an Independent Director of Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"As the approval of the reporting person as an Independent Director, and, to the extent one other Independent Director is serving, that other Independent Director, is needed for Roivant to dispose of the Common Shares, the reporting person may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Common Shares directly beneficially owned by Roivant. The reporting person disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his respective pecuniary interest therein. Additionally, this filing shall not be deemed an admission that the reporting person and any other Independent Director constitute a \"group\" for purposes of Section 13(d) or Section 13(g) of the Securities Exchange Act of 1934, as amended."}],"balance_after":22848350,"source":{"system":"sec-edgar","filing":"0001104659-19-036418","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679076/000110465919036418/a4.xml","form_type":"4"}},{"id":3488988,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-06-14T22:30:39.000Z","date":"2019-06-14","kind":"purchase","acquired":true,"shares":7144,"price":7.9107,"value":56514.0408,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made by Roivant Sciences Ltd. (\"Roivant\") under a trading plan established by Roivant pursuant to Rule 10b5-l under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. The purchases were made by Roivant and not by the Reporting Person. See footnotes 3 and 4 for information on the Reporting Person's ownership via Roivant of the purchased Common Shares."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.65 to $8.00, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These Common Shares are directly beneficially owned by Roivant and indirectly beneficially owned by the Reporting Person. Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an \"Independent Director\" and collectively the \"Independent Directors\"), dispositions of the Common Shares require the approval of a majority of Roivant's board of directors, including (i) at least two Independent Directors, or, (ii) if there is only one independent director, that sole Independent Director. The reporting person is an Independent Director of Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"As the approval of the reporting person as an Independent Director, and, to the extent one other Independent Director is serving, that other Independent Director, is needed for Roivant to dispose of the Common Shares, the reporting person may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Common Shares directly beneficially owned by Roivant. The reporting person disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his respective pecuniary interest therein. Additionally, this filing shall not be deemed an admission that the reporting person and any other Independent Director constitute a \"group\" for purposes of Section 13(d) or Section 13(g) of the Securities Exchange Act of 1934, as amended."}],"balance_after":22841809,"source":{"system":"sec-edgar","filing":"0001104659-19-035736","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1679076/000110465919035736/a4.xml","form_type":"4"}},{"id":3488987,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-06-14T22:30:39.000Z","date":"2019-06-13","kind":"purchase","acquired":true,"shares":7367,"price":7.9466,"value":58542.6022,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made by Roivant Sciences Ltd. (\"Roivant\") under a trading plan established by Roivant pursuant to Rule 10b5-l under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. The purchases were made by Roivant and not by the Reporting Person. See footnotes 3 and 4 for information on the Reporting Person's ownership via Roivant of the purchased Common Shares."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.67 to $8.39, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These Common Shares are directly beneficially owned by Roivant and indirectly beneficially owned by the Reporting Person. Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an \"Independent Director\" and collectively the \"Independent Directors\"), dispositions of the Common Shares require the approval of a majority of Roivant's board of directors, including (i) at least two Independent Directors, or, (ii) if there is only one independent director, that sole Independent Director. The reporting person is an Independent Director of Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"As the approval of the reporting person as an Independent Director, and, to the extent one other Independent Director is serving, that other Independent Director, is needed for Roivant to dispose of the Common Shares, the reporting person may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Common Shares directly beneficially owned by Roivant. The reporting person disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his respective pecuniary interest therein. Additionally, this filing shall not be deemed an admission that the reporting person and any other Independent Director constitute a \"group\" for purposes of Section 13(d) or Section 13(g) of the Securities Exchange Act of 1934, as amended."}],"balance_after":22834665,"source":{"system":"sec-edgar","filing":"0001104659-19-035736","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1679076/000110465919035736/a4.xml","form_type":"4"}},{"id":3488986,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-06-14T22:30:39.000Z","date":"2019-06-12","kind":"purchase","acquired":true,"shares":7500,"price":8.2992,"value":62244.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made by Roivant Sciences Ltd. (\"Roivant\") under a trading plan established by Roivant pursuant to Rule 10b5-l under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. The purchases were made by Roivant and not by the Reporting Person. See footnotes 3 and 4 for information on the Reporting Person's ownership via Roivant of the purchased Common Shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.16 to $8.77, inclusive. The reporting person undertakes to provide to Urovant Sciences Ltd. (\"Urovant\"), any security holder of Urovant, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These Common Shares are directly beneficially owned by Roivant and indirectly beneficially owned by the Reporting Person. Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an \"Independent Director\" and collectively the \"Independent Directors\"), dispositions of the Common Shares require the approval of a majority of Roivant's board of directors, including (i) at least two Independent Directors, or, (ii) if there is only one independent director, that sole Independent Director. The reporting person is an Independent Director of Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"As the approval of the reporting person as an Independent Director, and, to the extent one other Independent Director is serving, that other Independent Director, is needed for Roivant to dispose of the Common Shares, the reporting person may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Common Shares directly beneficially owned by Roivant. The reporting person disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his respective pecuniary interest therein. Additionally, this filing shall not be deemed an admission that the reporting person and any other Independent Director constitute a \"group\" for purposes of Section 13(d) or Section 13(g) of the Securities Exchange Act of 1934, as amended."}],"balance_after":22827298,"source":{"system":"sec-edgar","filing":"0001104659-19-035736","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679076/000110465919035736/a4.xml","form_type":"4"}},{"id":3493695,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-06-11T22:05:21.000Z","date":"2019-06-11","kind":"purchase","acquired":true,"shares":7189,"price":8.5817,"value":61693.8413,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made by Roivant Sciences Ltd. (\"Roivant\") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. The purchases were made by Roivant and not by the Reporting Person. See footnotes 3 and 4 for information on the Reporting Person's ownership via Roivant of the purchased Common Shares."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.41 to $8.75, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These Common Shares are directly beneficially owned by Roivant and indirectly beneficially owned by the Reporting Person. Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an \"Independent Director\" and collectively the \"Independent Directors\"), dispositions of the Common Shares require the approval of a majority of Roivant's board of directors, including (i) at least two Independent Directors, or, (ii) if there is only one independent\n director, that sole Independent Director. The reporting person is an Independent Director of Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"As the approval of the reporting person as an Independent Director, and, to the extent one other Independent Director is serving, that other Independent Director, is needed for Roivant to dispose of the Common Shares, the reporting person may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Common Shares directly beneficially owned by Roivant. The reporting person disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his respective pecuniary interest therein. Additionally, this filing shall not be deemed an admission that the reporting person and any other Independent Director constitute a \"group\" for purposes of Section 13(d) or Section 13(g) of the Securities Exchange Act of 1934, as amended."}],"balance_after":22819798,"source":{"system":"sec-edgar","filing":"0000919574-19-004081","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1679076/000091957419004081/ownership.xml","form_type":"4"}},{"id":3493694,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-06-11T22:05:21.000Z","date":"2019-06-10","kind":"purchase","acquired":true,"shares":7500,"price":8.3459,"value":62594.25,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made by Roivant Sciences Ltd. (\"Roivant\") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. The purchases were made by Roivant and not by the Reporting Person. See footnotes 3 and 4 for information on the Reporting Person's ownership via Roivant of the purchased Common Shares."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.89 to $8.68, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These Common Shares are directly beneficially owned by Roivant and indirectly beneficially owned by the Reporting Person. Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an \"Independent Director\" and collectively the \"Independent Directors\"), dispositions of the Common Shares require the approval of a majority of Roivant's board of directors, including (i) at least two Independent Directors, or, (ii) if there is only one independent\n director, that sole Independent Director. The reporting person is an Independent Director of Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"As the approval of the reporting person as an Independent Director, and, to the extent one other Independent Director is serving, that other Independent Director, is needed for Roivant to dispose of the Common Shares, the reporting person may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Common Shares directly beneficially owned by Roivant. The reporting person disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his respective pecuniary interest therein. Additionally, this filing shall not be deemed an admission that the reporting person and any other Independent Director constitute a \"group\" for purposes of Section 13(d) or Section 13(g) of the Securities Exchange Act of 1934, as amended."}],"balance_after":22812609,"source":{"system":"sec-edgar","filing":"0000919574-19-004081","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1679076/000091957419004081/ownership.xml","form_type":"4"}},{"id":3493693,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-06-11T22:05:21.000Z","date":"2019-06-07","kind":"purchase","acquired":true,"shares":6649,"price":7.965,"value":52959.285,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made by Roivant Sciences Ltd. (\"Roivant\") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. The purchases were made by Roivant and not by the Reporting Person. See footnotes 3 and 4 for information on the Reporting Person's ownership via Roivant of the purchased Common Shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.73 to $8.10, inclusive. The reporting person undertakes to provide to Urovant Sciences Ltd. (\"Urovant\"), any security holder of Urovant, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These Common Shares are directly beneficially owned by Roivant and indirectly beneficially owned by the Reporting Person. Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an \"Independent Director\" and collectively the \"Independent Directors\"), dispositions of the Common Shares require the approval of a majority of Roivant's board of directors, including (i) at least two Independent Directors, or, (ii) if there is only one independent\n director, that sole Independent Director. The reporting person is an Independent Director of Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"As the approval of the reporting person as an Independent Director, and, to the extent one other Independent Director is serving, that other Independent Director, is needed for Roivant to dispose of the Common Shares, the reporting person may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Common Shares directly beneficially owned by Roivant. The reporting person disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his respective pecuniary interest therein. Additionally, this filing shall not be deemed an admission that the reporting person and any other Independent Director constitute a \"group\" for purposes of Section 13(d) or Section 13(g) of the Securities Exchange Act of 1934, as amended."}],"balance_after":22805109,"source":{"system":"sec-edgar","filing":"0000919574-19-004081","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679076/000091957419004081/ownership.xml","form_type":"4"}},{"id":3498336,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-06-06T22:08:53.000Z","date":"2019-06-06","kind":"purchase","acquired":true,"shares":7082,"price":7.9951,"value":56621.2982,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made by Roivant Sciences Ltd. (\"Roivant\") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. The purchases were made by Roivant and not by the Reporting Person. See footnotes 3 and 4 for information on the Reporting Person's ownership via Roivant of the purchased Common Shares."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.73 to $8.57, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These Common Shares are directly beneficially owned by Roivant and indirectly beneficially owned by the Reporting Person. Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an \"Independent Director\" and collectively the \"Independent Directors\"), dispositions of the Common Shares require the approval of a majority of Roivant's board of directors, including (i) at least two Independent Directors, or, (ii) if there is only one independent\n director, that sole Independent Director. The reporting person is an Independent Director of Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"As the approval of the reporting person as an Independent Director, and, to the extent one other Independent Director is serving, that other Independent Director, is needed for Roivant to dispose of the Common Shares, the reporting person may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Common Shares directly beneficially owned by Roivant. The reporting person disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his respective pecuniary interest therein. Additionally, this filing shall not be deemed an admission that the reporting person and any other Independent Director constitute a \"group\" for purposes of Section 13(d) or Section 13(g) of the Securities Exchange Act of 1934, as amended."}],"balance_after":22798460,"source":{"system":"sec-edgar","filing":"0000919574-19-003994","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1679076/000091957419003994/ownership.xml","form_type":"4"}},{"id":3498335,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-06-06T22:08:53.000Z","date":"2019-06-05","kind":"purchase","acquired":true,"shares":6540,"price":8.015,"value":52418.1,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made by Roivant Sciences Ltd. (\"Roivant\") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. The purchases were made by Roivant and not by the Reporting Person. See footnotes 3 and 4 for information on the Reporting Person's ownership via Roivant of the purchased Common Shares."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.68 to $8.33, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These Common Shares are directly beneficially owned by Roivant and indirectly beneficially owned by the Reporting Person. Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an \"Independent Director\" and collectively the \"Independent Directors\"), dispositions of the Common Shares require the approval of a majority of Roivant's board of directors, including (i) at least two Independent Directors, or, (ii) if there is only one independent\n director, that sole Independent Director. The reporting person is an Independent Director of Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"As the approval of the reporting person as an Independent Director, and, to the extent one other Independent Director is serving, that other Independent Director, is needed for Roivant to dispose of the Common Shares, the reporting person may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Common Shares directly beneficially owned by Roivant. The reporting person disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his respective pecuniary interest therein. Additionally, this filing shall not be deemed an admission that the reporting person and any other Independent Director constitute a \"group\" for purposes of Section 13(d) or Section 13(g) of the Securities Exchange Act of 1934, as amended."}],"balance_after":22791378,"source":{"system":"sec-edgar","filing":"0000919574-19-003994","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1679076/000091957419003994/ownership.xml","form_type":"4"}},{"id":3498334,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-06-06T22:08:53.000Z","date":"2019-06-04","kind":"purchase","acquired":true,"shares":7500,"price":7.5881,"value":56910.75,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made by Roivant Sciences Ltd. (\"Roivant\") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. The purchases were made by Roivant and not by the Reporting Person. See footnotes 3 and 4 for information on the Reporting Person's ownership via Roivant of the purchased Common Shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.42 to $7.71, inclusive. The reporting person undertakes to provide to Urovant Sciences Ltd. (\"Urovant\"), any security holder of Urovant, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These Common Shares are directly beneficially owned by Roivant and indirectly beneficially owned by the Reporting Person. Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an \"Independent Director\" and collectively the \"Independent Directors\"), dispositions of the Common Shares require the approval of a majority of Roivant's board of directors, including (i) at least two Independent Directors, or, (ii) if there is only one independent\n director, that sole Independent Director. The reporting person is an Independent Director of Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"As the approval of the reporting person as an Independent Director, and, to the extent one other Independent Director is serving, that other Independent Director, is needed for Roivant to dispose of the Common Shares, the reporting person may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Common Shares directly beneficially owned by Roivant. The reporting person disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his respective pecuniary interest therein. Additionally, this filing shall not be deemed an admission that the reporting person and any other Independent Director constitute a \"group\" for purposes of Section 13(d) or Section 13(g) of the Securities Exchange Act of 1934, as amended."}],"balance_after":22784838,"source":{"system":"sec-edgar","filing":"0000919574-19-003994","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679076/000091957419003994/ownership.xml","form_type":"4"}},{"id":3498305,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, $0.000017727 par value per share","published_at":"2019-06-06T22:07:40.000Z","date":"2019-06-04","kind":"purchase","acquired":true,"shares":2424242,"price":8.25,"value":19999996.5,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These Common Shares were purchased by Roivant Sciences Ltd. (\"Roivant\") in connection with an underwritten public offering of Common Shares by Myovant Sciences Ltd. The Common Shares are directly beneficially owned by Roivant and indirectly beneficially owned by the reporting person. Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an \"Independent Director\" and collectively the \"Independent Directors\"), dispositions of the Common Shares require the approval of a majority of Roivant's board of directors, including (i) at least two Independent Directors, or, (ii) if there is only one Independent Director, that sole Independent Director."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reporting person is an Independent Director of Roivant. As the approval of the reporting person as an Independent Director, and, to the extent one other Independent Director is serving, that other Independent Director, is needed for Roivant to dispose of the Common Shares, the reporting person may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Common Shares directly beneficially owned by Roivant. The reporting person disclaims beneficial ownership of the Common Shares owned by Roivant, except to the extent of his respective pecuniary interest therein. This filing shall not be deemed an admission that the reporting person and any other Independent Director constitute a \"group\" for purposes of Section 13(d) or Section 13(g) of the Securities Exchange Act of 1934, as amended."}],"balance_after":40765599,"source":{"system":"sec-edgar","filing":"0000919574-19-003993","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679076/000091957419003993/ownership.xml","form_type":"4"}},{"id":3504231,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-06-03T22:13:43.000Z","date":"2019-06-03","kind":"purchase","acquired":true,"shares":5424,"price":7.7092,"value":41814.7008,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made by Roivant Sciences Ltd. (\"Roivant\") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. The purchases were made by Roivant and not by the Reporting Person. See footnotes 3 and 4 for information on the Reporting Person's ownership via Roivant of the purchased Common Shares."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.64 to $7.74, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (7) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These Common Shares are directly beneficially owned by Roivant and indirectly beneficially owned by the Reporting Person. Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an \"Independent Director\" and collectively the \"Independent Directors\"), dispositions of the Common Shares require the approval of a majority of Roivant's board of directors, including (i) at least two Independent Directors, or, (ii) if there is only one independent\n director, that sole Independent Director. The reporting person is an Independent Director of Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"As the approval of the reporting person as an Independent Director, and, to the extent one other Independent Director is serving, that other Independent Director, is needed for Roivant to dispose of the Common Shares, the reporting person may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Common Shares directly beneficially owned by Roivant. The reporting person disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his respective pecuniary interest therein. Additionally, this filing shall not be deemed an admission that the reporting person and any other Independent Director constitute a \"group\" for purposes of Section 13(d) or Section 13(g) of the Securities Exchange Act of 1934, as amended."}],"balance_after":22777338,"source":{"system":"sec-edgar","filing":"0000919574-19-003949","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1679076/000091957419003949/ownership.xml","form_type":"4"}},{"id":3504230,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-06-03T22:13:43.000Z","date":"2019-05-31","kind":"purchase","acquired":true,"shares":5071,"price":7.6991,"value":39042.1361,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made by Roivant Sciences Ltd. (\"Roivant\") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. The purchases were made by Roivant and not by the Reporting Person. See footnotes 3 and 4 for information on the Reporting Person's ownership via Roivant of the purchased Common Shares."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.41 to $7.84, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These Common Shares are directly beneficially owned by Roivant and indirectly beneficially owned by the Reporting Person. Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an \"Independent Director\" and collectively the \"Independent Directors\"), dispositions of the Common Shares require the approval of a majority of Roivant's board of directors, including (i) at least two Independent Directors, or, (ii) if there is only one independent\n director, that sole Independent Director. The reporting person is an Independent Director of Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"As the approval of the reporting person as an Independent Director, and, to the extent one other Independent Director is serving, that other Independent Director, is needed for Roivant to dispose of the Common Shares, the reporting person may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Common Shares directly beneficially owned by Roivant. The reporting person disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his respective pecuniary interest therein. Additionally, this filing shall not be deemed an admission that the reporting person and any other Independent Director constitute a \"group\" for purposes of Section 13(d) or Section 13(g) of the Securities Exchange Act of 1934, as amended."}],"balance_after":22771914,"source":{"system":"sec-edgar","filing":"0000919574-19-003949","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1679076/000091957419003949/ownership.xml","form_type":"4"}},{"id":3504229,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-06-03T22:13:43.000Z","date":"2019-05-30","kind":"purchase","acquired":true,"shares":300,"price":8.9066,"value":2671.98,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made by Roivant Sciences Ltd. (\"Roivant\") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. The purchases were made by Roivant and not by the Reporting Person. See footnotes 3 and 4 for information on the Reporting Person's ownership via Roivant of the purchased Common Shares."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $8.71 to $9.03, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These Common Shares are directly beneficially owned by Roivant and indirectly beneficially owned by the Reporting Person. Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an \"Independent Director\" and collectively the \"Independent Directors\"), dispositions of the Common Shares require the approval of a majority of Roivant's board of directors, including (i) at least two Independent Directors, or, (ii) if there is only one independent\n director, that sole Independent Director. The reporting person is an Independent Director of Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"As the approval of the reporting person as an Independent Director, and, to the extent one other Independent Director is serving, that other Independent Director, is needed for Roivant to dispose of the Common Shares, the reporting person may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Common Shares directly beneficially owned by Roivant. The reporting person disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his respective pecuniary interest therein. Additionally, this filing shall not be deemed an admission that the reporting person and any other Independent Director constitute a \"group\" for purposes of Section 13(d) or Section 13(g) of the Securities Exchange Act of 1934, as amended."}],"balance_after":22766843,"source":{"system":"sec-edgar","filing":"0000919574-19-003949","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1679076/000091957419003949/ownership.xml","form_type":"4"}},{"id":3504228,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-06-03T22:13:43.000Z","date":"2019-05-30","kind":"purchase","acquired":true,"shares":6951,"price":7.9726,"value":55417.5426,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made by Roivant Sciences Ltd. (\"Roivant\") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. The purchases were made by Roivant and not by the Reporting Person. See footnotes 3 and 4 for information on the Reporting Person's ownership via Roivant of the purchased Common Shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.70 to $8.70, inclusive. The reporting person undertakes to provide to Urovant Sciences Ltd. (\"Urovant\"), any security holder of Urovant, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These Common Shares are directly beneficially owned by Roivant and indirectly beneficially owned by the Reporting Person. Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an \"Independent Director\" and collectively the \"Independent Directors\"), dispositions of the Common Shares require the approval of a majority of Roivant's board of directors, including (i) at least two Independent Directors, or, (ii) if there is only one independent\n director, that sole Independent Director. The reporting person is an Independent Director of Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"As the approval of the reporting person as an Independent Director, and, to the extent one other Independent Director is serving, that other Independent Director, is needed for Roivant to dispose of the Common Shares, the reporting person may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Common Shares directly beneficially owned by Roivant. The reporting person disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his respective pecuniary interest therein. Additionally, this filing shall not be deemed an admission that the reporting person and any other Independent Director constitute a \"group\" for purposes of Section 13(d) or Section 13(g) of the Securities Exchange Act of 1934, as amended."}],"balance_after":22766543,"source":{"system":"sec-edgar","filing":"0000919574-19-003949","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679076/000091957419003949/ownership.xml","form_type":"4"}},{"id":3508298,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-05-29T22:12:34.000Z","date":"2019-05-29","kind":"purchase","acquired":true,"shares":6882,"price":7.5535,"value":51983.187,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made by Roivant Sciences Ltd. (\"Roivant\") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. The purchases were made by Roivant and not by the Reporting Person. See footnotes 3 and 4 for information on the Reporting Person's ownership via Roivant of the purchased Common Shares."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.40 to $7.69, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (6) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These Common Shares are directly beneficially owned by Roivant and indirectly beneficially owned by the Reporting Person. Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an \"Independent Director\" and collectively the \"Independent Directors\"), dispositions of the Common Shares require the approval of a majority of Roivant's board of directors, including (i) at least two Independent Directors, or, (ii) if there is only one independent director, that sole Independent Director. The reporting person is an Independent Director of Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"As the approval of the reporting person as an Independent Director, and, to the extent one other Independent Director is serving, that other Independent Director, is needed for Roivant to dispose of the Common Shares, the reporting person may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Common Shares directly beneficially owned by Roivant. The reporting person disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his respective pecuniary interest therein. Additionally, this filing shall not be deemed an admission that the reporting person and any other Independent Director constitute a \"group\" for purposes of Section 13(d) or Section 13(g) of the Securities Exchange Act of 1934, as amended."}],"balance_after":22759592,"source":{"system":"sec-edgar","filing":"0000919574-19-003880","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1679076/000091957419003880/ownership.xml","form_type":"4"}},{"id":3508297,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-05-29T22:12:34.000Z","date":"2019-05-28","kind":"purchase","acquired":true,"shares":3807,"price":7.6818,"value":29244.6126,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made by Roivant Sciences Ltd. (\"Roivant\") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. The purchases were made by Roivant and not by the Reporting Person. See footnotes 3 and 4 for information on the Reporting Person's ownership via Roivant of the purchased Common Shares."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.65 to $7.70, inclusive. The reporting person undertakes to provide to Urovant, any security holder of Urovant, or the staff of the SEC, upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (5) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These Common Shares are directly beneficially owned by Roivant and indirectly beneficially owned by the Reporting Person. Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an \"Independent Director\" and collectively the \"Independent Directors\"), dispositions of the Common Shares require the approval of a majority of Roivant's board of directors, including (i) at least two Independent Directors, or, (ii) if there is only one independent director, that sole Independent Director. The reporting person is an Independent Director of Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"As the approval of the reporting person as an Independent Director, and, to the extent one other Independent Director is serving, that other Independent Director, is needed for Roivant to dispose of the Common Shares, the reporting person may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Common Shares directly beneficially owned by Roivant. The reporting person disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his respective pecuniary interest therein. Additionally, this filing shall not be deemed an admission that the reporting person and any other Independent Director constitute a \"group\" for purposes of Section 13(d) or Section 13(g) of the Securities Exchange Act of 1934, as amended."}],"balance_after":22752710,"source":{"system":"sec-edgar","filing":"0000919574-19-003880","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1679076/000091957419003880/ownership.xml","form_type":"4"}},{"id":3508296,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-05-29T22:12:34.000Z","date":"2019-05-24","kind":"purchase","acquired":true,"shares":3796,"price":7.7011,"value":29233.3756,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The transaction was a series of open market purchases made by Roivant Sciences Ltd. (\"Roivant\") under a trading plan established by Roivant pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), and in accordance with the safe harbor of Rule 10b-18 under the Exchange Act. The purchases were made by Roivant and not by the Reporting Person. See footnotes 3 and 4 for information on the Reporting Person's ownership via Roivant of the purchased Common Shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These Common Shares were purchased in multiple transactions at prices ranging from $7.66 to $7.74, inclusive. The reporting person undertakes to provide to Urovant Sciences Ltd. (\"Urovant\"), any security holder of Urovant, or the staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of Common Shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These Common Shares are directly beneficially owned by Roivant and indirectly beneficially owned by the Reporting Person. Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an \"Independent Director\" and collectively the \"Independent Directors\"), dispositions of the Common Shares require the approval of a majority of Roivant's board of directors, including (i) at least two Independent Directors, or, (ii) if there is only one independent director, that sole Independent Director. The reporting person is an Independent Director of Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"As the approval of the reporting person as an Independent Director, and, to the extent one other Independent Director is serving, that other Independent Director, is needed for Roivant to dispose of the Common Shares, the reporting person may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Common Shares directly beneficially owned by Roivant. The reporting person disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his respective pecuniary interest therein. Additionally, this filing shall not be deemed an admission that the reporting person and any other Independent Director constitute a \"group\" for purposes of Section 13(d) or Section 13(g) of the Securities Exchange Act of 1934, as amended."}],"balance_after":22748903,"source":{"system":"sec-edgar","filing":"0000919574-19-003880","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679076/000091957419003880/ownership.xml","form_type":"4"}},{"id":3513022,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-05-23T22:21:31.000Z","date":"2019-05-23","kind":"purchase","acquired":true,"shares":4802,"price":7.7576,"value":37251.9952,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These Common Shares are directly beneficially owned by Roivant Sciences Ltd. (\"Roivant\"). Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an \"Independent Director\" and collectively the \"Independent Directors\"), dispositions of the Common Shares require the approval of a majority of Roivant's board of directors, including (i) at least two Independent Directors, or, (ii) if there is only one independent director, that sole Independent Director. The reporting person is an Independent Director of Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"As the approval of the reporting person as an Independent Director, and, to the extent one other Independent Director is serving, that other Independent Director, is needed for Roivant to dispose of the Common Shares, the reporting person may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Common Shares directly beneficially owned by Roivant. The reporting person disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his respective pecuniary interest therein. Additionally, this filing shall not be deemed an admission that the reporting person and any other Independent Director constitute a \"group\" for purposes of Section 13(d) or Section 13(g) of the Securities Exchange Act of 1934, as amended."}],"balance_after":22745107,"source":{"system":"sec-edgar","filing":"0000919574-19-003830","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1679076/000091957419003830/ownership.xml","form_type":"4"}},{"id":3513021,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-05-23T22:21:31.000Z","date":"2019-05-22","kind":"purchase","acquired":true,"shares":5033,"price":8.0584,"value":40557.9272,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These Common Shares are directly beneficially owned by Roivant Sciences Ltd. (\"Roivant\"). Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an \"Independent Director\" and collectively the \"Independent Directors\"), dispositions of the Common Shares require the approval of a majority of Roivant's board of directors, including (i) at least two Independent Directors, or, (ii) if there is only one independent director, that sole Independent Director. The reporting person is an Independent Director of Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"As the approval of the reporting person as an Independent Director, and, to the extent one other Independent Director is serving, that other Independent Director, is needed for Roivant to dispose of the Common Shares, the reporting person may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Common Shares directly beneficially owned by Roivant. The reporting person disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his respective pecuniary interest therein. Additionally, this filing shall not be deemed an admission that the reporting person and any other Independent Director constitute a \"group\" for purposes of Section 13(d) or Section 13(g) of the Securities Exchange Act of 1934, as amended."}],"balance_after":22740305,"source":{"system":"sec-edgar","filing":"0000919574-19-003830","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1679076/000091957419003830/ownership.xml","form_type":"4"}},{"id":3513020,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-05-23T22:21:31.000Z","date":"2019-05-21","kind":"purchase","acquired":true,"shares":9995,"price":8.5151,"value":85108.4245,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These Common Shares are directly beneficially owned by Roivant Sciences Ltd. (\"Roivant\"). Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an \"Independent Director\" and collectively the \"Independent Directors\"), dispositions of the Common Shares require the approval of a majority of Roivant's board of directors, including (i) at least two Independent Directors, or, (ii) if there is only one independent director, that sole Independent Director. The reporting person is an Independent Director of Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"As the approval of the reporting person as an Independent Director, and, to the extent one other Independent Director is serving, that other Independent Director, is needed for Roivant to dispose of the Common Shares, the reporting person may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Common Shares directly beneficially owned by Roivant. The reporting person disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his respective pecuniary interest therein. Additionally, this filing shall not be deemed an admission that the reporting person and any other Independent Director constitute a \"group\" for purposes of Section 13(d) or Section 13(g) of the Securities Exchange Act of 1934, as amended."}],"balance_after":22735272,"source":{"system":"sec-edgar","filing":"0000919574-19-003830","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679076/000091957419003830/ownership.xml","form_type":"4"}},{"id":3517975,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-05-20T22:46:27.000Z","date":"2019-05-20","kind":"purchase","acquired":true,"shares":1715,"price":8.3867,"value":14383.1905,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These Common Shares are directly beneficially owned by Roivant Sciences Ltd. (\"Roivant\"). Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an \"Independent Director\" and collectively the \"Independent Directors\"), dispositions of the Common Shares require the approval of a majority of Roivant's board of directors, including (i) at least two Independent Directors, or, (ii) if there is only one independent director, that sole Independent Director. The reporting person is an Independent Director of Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"As the approval of the reporting person as an Independent Director, and, to the extent one other Independent Director is serving, that other Independent Director, is needed for Roivant to dispose of the Common Shares, the reporting person may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Common Shares directly beneficially owned by Roivant. The reporting person disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his respective pecuniary interest therein. Additionally, this filing shall not be deemed an admission that the reporting person and any other Independent Director constitute a \"group\" for purposes of Section 13(d) or Section 13(g) of the Securities Exchange Act of 1934, as amended."}],"balance_after":22725277,"source":{"system":"sec-edgar","filing":"0000919574-19-003792","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1679076/000091957419003792/ownership.xml","form_type":"4"}},{"id":3517974,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-05-20T22:46:27.000Z","date":"2019-05-20","kind":"purchase","acquired":true,"shares":8285,"price":7.9833,"value":66141.6405,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These Common Shares are directly beneficially owned by Roivant Sciences Ltd. (\"Roivant\"). Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an \"Independent Director\" and collectively the \"Independent Directors\"), dispositions of the Common Shares require the approval of a majority of Roivant's board of directors, including (i) at least two Independent Directors, or, (ii) if there is only one independent director, that sole Independent Director. The reporting person is an Independent Director of Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"As the approval of the reporting person as an Independent Director, and, to the extent one other Independent Director is serving, that other Independent Director, is needed for Roivant to dispose of the Common Shares, the reporting person may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Common Shares directly beneficially owned by Roivant. The reporting person disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his respective pecuniary interest therein. Additionally, this filing shall not be deemed an admission that the reporting person and any other Independent Director constitute a \"group\" for purposes of Section 13(d) or Section 13(g) of the Securities Exchange Act of 1934, as amended."}],"balance_after":22723562,"source":{"system":"sec-edgar","filing":"0000919574-19-003792","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1679076/000091957419003792/ownership.xml","form_type":"4"}},{"id":3517973,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-05-20T22:46:27.000Z","date":"2019-05-17","kind":"purchase","acquired":true,"shares":6200,"price":7.3615,"value":45641.3,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These Common Shares are directly beneficially owned by Roivant Sciences Ltd. (\"Roivant\"). Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an \"Independent Director\" and collectively the \"Independent Directors\"), dispositions of the Common Shares require the approval of a majority of Roivant's board of directors, including (i) at least two Independent Directors, or, (ii) if there is only one independent director, that sole Independent Director. The reporting person is an Independent Director of Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"As the approval of the reporting person as an Independent Director, and, to the extent one other Independent Director is serving, that other Independent Director, is needed for Roivant to dispose of the Common Shares, the reporting person may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Common Shares directly beneficially owned by Roivant. The reporting person disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his respective pecuniary interest therein. Additionally, this filing shall not be deemed an admission that the reporting person and any other Independent Director constitute a \"group\" for purposes of Section 13(d) or Section 13(g) of the Securities Exchange Act of 1934, as amended."}],"balance_after":22715277,"source":{"system":"sec-edgar","filing":"0000919574-19-003792","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1679076/000091957419003792/ownership.xml","form_type":"4"}},{"id":3517972,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.000037453 per share","published_at":"2019-05-20T22:46:27.000Z","date":"2019-05-16","kind":"purchase","acquired":true,"shares":5408,"price":6.7896,"value":36718.1568,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These Common Shares are directly beneficially owned by Roivant Sciences Ltd. (\"Roivant\"). Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an \"Independent Director\" and collectively the \"Independent Directors\"), dispositions of the Common Shares require the approval of a majority of Roivant's board of directors, including (i) at least two Independent Directors, or, (ii) if there is only one independent director, that sole Independent Director. The reporting person is an Independent Director of Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"As the approval of the reporting person as an Independent Director, and, to the extent one other Independent Director is serving, that other Independent Director, is needed for Roivant to dispose of the Common Shares, the reporting person may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Common Shares directly beneficially owned by Roivant. The reporting person disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his respective pecuniary interest therein. Additionally, this filing shall not be deemed an admission that the reporting person and any other Independent Director constitute a \"group\" for purposes of Section 13(d) or Section 13(g) of the Securities Exchange Act of 1934, as amended."}],"balance_after":22709077,"source":{"system":"sec-edgar","filing":"0000919574-19-003792","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679076/000091957419003792/ownership.xml","form_type":"4"}},{"id":3585614,"issuer":{"id":130622,"kind":"organization","name":"Sio Gene Therapies Inc.","symbol":"SIOX"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.00001 per share","published_at":"2019-03-19T16:49:32.000Z","date":"2019-03-18","kind":"purchase","acquired":true,"shares":6666667,"price":1.5,"value":10000000.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These Common Shares are directly beneficially owned by Roivant Sciences Ltd. (\"Roivant\"). Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an \"Independent Director\" and collectively the \"Independent Directors\"), dispositions of the Common Shares require the approval of a majority of Roivant's board of directors, including (i) at least two Independent Directors, or, (ii) if there is only one independent director, that sole Independent Director. The reporting person was appointed as an Independent Director of Roivant effective October 18, 2016."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"As the approval of the reporting person as an Independent Director, and, to the extent one other Independent Director is serving, that other Independent Director, is needed for Roivant to dispose of the Common Shares, the reporting person may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Common Shares directly beneficially owned by Roivant. The reporting person disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his respective pecuniary interest therein. Additionally, this filing shall not be deemed an admission that the reporting person and any other Independent Director constitute a \"group\" for purposes of Section 13(d) or Section 13(g) of the Securities Exchange Act of 1934, as amended."}],"balance_after":105952381,"source":{"system":"sec-edgar","filing":"0001104659-19-016034","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636050/000110465919016034/a4.xml","form_type":"4"}},{"id":3723102,"issuer":{"id":130622,"kind":"organization","name":"Sio Gene Therapies Inc.","symbol":"SIOX"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.00001 per share","published_at":"2018-12-20T08:57:54.000Z","date":"2018-12-18","kind":"purchase","acquired":true,"shares":10000000,"price":1,"value":10000000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These Common Shares are directly beneficially owned by Roivant Sciences Ltd. (\"Roivant\"). Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an \"Independent Director\" and collectively the \"Independent Directors\"), dispositions of the Common Shares require the approval of a majority of Roivant's board of directors, including (i) at least two Independent Directors, or, (ii) if there is only one independent director, that sole Independent Director. The reporting person was appointed as an Independent Director of Roivant effective October 18, 2016."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"As the approval of the reporting person as an Independent Director, and, to the extent one other Independent Director is serving, that other Independent Director, is needed for Roivant to dispose of the Common Shares, the reporting person may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Common Shares directly beneficially owned by Roivant. The reporting person disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his respective pecuniary interest therein. Additionally, this filing shall not be deemed an admission that the reporting person and any other Independent Director constitute a \"group\" for purposes of Section 13(d) or Section 13(g) of the Securities Exchange Act of 1934, as amended."}],"balance_after":99285714,"source":{"system":"sec-edgar","filing":"0001104659-18-073942","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636050/000110465918073942/a4.xml","form_type":"4"}},{"id":3797762,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, $0.000037453 par value per share","published_at":"2018-10-03T23:18:41.000Z","date":"2018-10-01","kind":"purchase","acquired":true,"shares":2678571,"price":14,"value":37499994.0,"ownership":{"direct":false,"nature":"See footnote."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These Common Shares are directly beneficially owned by Roivant Sciences Ltd. (\"Roivant\"). Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an \"Independent Director\" and collectively the \"Independent Directors\"), dispositions of the Common Shares require the approval of a majority of Roivant's board of directors, including (i) at least two Independent Directors, or, (ii) if there is only one independent director, that sole Independent Director. The reporting person is an Independent Director of Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"As the approval of the reporting person as an Independent Director, and, to the extent one other Independent Director is serving, that other Independent Director, is needed for Roivant to dispose of the Common Shares, the reporting person may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Common Shares directly beneficially owned by Roivant. The reporting person disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his respective pecuniary interest therein. Additionally, this filing shall not be deemed an admission that the reporting person and any other Independent Director constitute a \"group\" for purposes of Section 13(d) or Section 13(g) of the Securities Exchange Act of 1934, as amended."}],"balance_after":22703669,"source":{"system":"sec-edgar","filing":"0001104659-18-060388","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679076/000110465918060388/a4.xml","form_type":"4"}},{"id":3901191,"issuer":{"id":130622,"kind":"organization","name":"Sio Gene Therapies Inc.","symbol":"SIOX"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, par value $0.00001 per share","published_at":"2018-06-07T08:46:15.000Z","date":"2018-06-05","kind":"purchase","acquired":true,"shares":14285714,"price":1.75,"value":24999999.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These Common Shares are directly beneficially owned by Roivant Sciences Ltd. (\"Roivant\"). Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an \"Independent Director\" and collectively the \"Independent Directors\"), dispositions of the Common Shares require the approval of a majority of Roivant's board of directors, including (i) at least two Independent Directors, or, (ii) if there is only one independent director, that sole Independent Director. The reporting person was appointed as an Independent Director of Roivant effective October 18, 2016."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"As the approval of the reporting person as an Independent Director, and, to the extent one other Independent Director is serving, that other Independent Director, is needed for Roivant to dispose of the Common Shares, the reporting person may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Common Shares directly beneficially owned by Roivant. The reporting person disclaims beneficial ownership of the shares owned by Roivant, except to the extent of his respective pecuniary interest therein. Additionally, this filing shall not be deemed an admission that the reporting person and any other Independent Director constitute a \"group\" for purposes of Section 13(d) or Section 13(g) of the Securities Exchange Act of 1934, as amended."}],"balance_after":89285714,"source":{"system":"sec-edgar","filing":"0001104659-18-038782","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1636050/000110465918038782/a4.xml","form_type":"4"}},{"id":3968980,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares, $0.000017727 par value per share","published_at":"2018-04-04T21:00:56.000Z","date":"2018-04-02","kind":"purchase","acquired":true,"shares":1110015,"price":20.27,"value":22500004.05,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The Shares are directly beneficially owned by Roivant Sciences Ltd. (\"Roivant\"). Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an \"Independent Director\" and collectively the \"Independent Directors\"), dispositions of the Shares require the approval of a majority of Roivant's board of directors, including (i) at least two Independent Directors, or, (ii) if there is only one Independent Director, that sole Independent Director."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reporting person is an Independent Director of Roivant. As the approval of the reporting person as an Independent Director, and, to the extent one other Independent Director is serving, that other Independent Director, is needed for Roivant to dispose of the Shares, the reporting person may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Shares directly beneficially owned by Roivant. The reporting person disclaims beneficial ownership of the Shares owned by Roivant, except to the extent of his respective pecuniary interest therein. This filing shall not be deemed an admission that the reporting person and any other Independent Director constitute a \"group\" for purposes of Section 13(d) or Section 13(g) of the Securities Exchange Act of 1934, as amended."}],"balance_after":38341357,"source":{"system":"sec-edgar","filing":"0001104659-18-022441","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679076/000110465918022441/a4.xml","form_type":"4"}},{"id":4099320,"issuer":{"id":4953,"kind":"organization","name":"Arbutus Biopharma Corp","symbol":"ABUS"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Participating Convertible Preferred Shares","published_at":"2018-01-16T12:30:20.000Z","date":"2018-01-12","kind":"purchase","acquired":true,"shares":664000,"price":100,"value":66400000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents series A participating convertible preferred shares (the \"Preferred Shares\") purchased by Roivant Sciences Ltd. (\"Roivant\") for $100.00 per Preferred Share (the \"Purchase Price\"), which price is subject to increase to reflect the addition of any unpaid participating cash dividends and unpaid participating in-kind dividends."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price, plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents series A participating convertible preferred shares (the \"Preferred Shares\") purchased by Roivant Sciences Ltd. (\"Roivant\") for $100.00 per Preferred Share (the \"Purchase Price\"), which price is subject to increase to reflect the addition of any unpaid participating cash dividends and unpaid participating in-kind dividends."},{"field":"shares","element":"transactionShares","label":"F2","text":"Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price, plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents series A participating convertible preferred shares (the \"Preferred Shares\") purchased by Roivant Sciences Ltd. (\"Roivant\") for $100.00 per Preferred Share (the \"Purchase Price\"), which price is subject to increase to reflect the addition of any unpaid participating cash dividends and unpaid participating in-kind dividends."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price, plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents series A participating convertible preferred shares (the \"Preferred Shares\") purchased by Roivant Sciences Ltd. (\"Roivant\") for $100.00 per Preferred Share (the \"Purchase Price\"), which price is subject to increase to reflect the addition of any unpaid participating cash dividends and unpaid participating in-kind dividends."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price, plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents series A participating convertible preferred shares (the \"Preferred Shares\") purchased by Roivant Sciences Ltd. (\"Roivant\") for $100.00 per Preferred Share (the \"Purchase Price\"), which price is subject to increase to reflect the addition of any unpaid participating cash dividends and unpaid participating in-kind dividends."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price, plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Represents series A participating convertible preferred shares (the \"Preferred Shares\") purchased by Roivant Sciences Ltd. (\"Roivant\") for $100.00 per Preferred Share (the \"Purchase Price\"), which price is subject to increase to reflect the addition of any unpaid participating cash dividends and unpaid participating in-kind dividends."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price, plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Preferred Shares are directly beneficially owned by Roivant. Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an \"Independent Director\" and collectively the \"Independent Directors\"), dispositions of the Preferred Shares require the approval of a majority of Roivant's board of directors, including (i) at least two Independent Directors, or, (ii) if there is only one Independent Director, that sole Independent Director."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reporting person is an Independent Director of Roivant. As the approval of the reporting person as an Independent Director, and, to the extent one other Independent Director is serving, that other Independent Director, is needed for Roivant to dispose of the Preferred Shares, the reporting person may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Preferred Shares directly beneficially owned by Roivant. The reporting person disclaims beneficial ownership of the Preferred Shares owned by Roivant, except to the extent of his respective pecuniary interest therein. This filing shall not be deemed an admission that the reporting person and any other Independent Director constitute a \"group\" for purposes of Section 13(d) or Section 13(g) of the Securities Exchange Act of 1934, as amended."}],"balance_after":1164000,"derivative":{"exercise_price":7.13,"expiration_date":"2021-10-16","underlying":"Common shares, no par value","underlying_shares":13025536},"source":{"system":"sec-edgar","filing":"0001104659-18-002226","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1447028/000110465918002226/a4.xml","form_type":"4"}},{"id":4184853,"issuer":{"id":4953,"kind":"organization","name":"Arbutus Biopharma Corp","symbol":"ABUS"},"owners":[{"id":35667,"kind":"person","name":"Lo Andrew","position":1,"cik":"0001679076","reported_name":"Lo Andrew","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Participating Convertible Preferred Shares","published_at":"2017-10-17T12:19:33.000Z","date":"2017-10-16","kind":"purchase","acquired":true,"shares":500000,"price":100,"value":50000000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents series A participating convertible preferred shares (the \"Preferred Shares\") purchased by Roivant Sciences Ltd. (\"Roivant\") for $100.00 per Preferred Share (the \"Purchase Price\"), which price is subject to increase to reflect the addition of any unpaid participating cash dividends and unpaid participating in-kind dividends."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price, plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents series A participating convertible preferred shares (the \"Preferred Shares\") purchased by Roivant Sciences Ltd. (\"Roivant\") for $100.00 per Preferred Share (the \"Purchase Price\"), which price is subject to increase to reflect the addition of any unpaid participating cash dividends and unpaid participating in-kind dividends."},{"field":"shares","element":"transactionShares","label":"F2","text":"Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price, plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents series A participating convertible preferred shares (the \"Preferred Shares\") purchased by Roivant Sciences Ltd. (\"Roivant\") for $100.00 per Preferred Share (the \"Purchase Price\"), which price is subject to increase to reflect the addition of any unpaid participating cash dividends and unpaid participating in-kind dividends."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price, plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents series A participating convertible preferred shares (the \"Preferred Shares\") purchased by Roivant Sciences Ltd. (\"Roivant\") for $100.00 per Preferred Share (the \"Purchase Price\"), which price is subject to increase to reflect the addition of any unpaid participating cash dividends and unpaid participating in-kind dividends."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price, plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents series A participating convertible preferred shares (the \"Preferred Shares\") purchased by Roivant Sciences Ltd. (\"Roivant\") for $100.00 per Preferred Share (the \"Purchase Price\"), which price is subject to increase to reflect the addition of any unpaid participating cash dividends and unpaid participating in-kind dividends."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price, plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Represents series A participating convertible preferred shares (the \"Preferred Shares\") purchased by Roivant Sciences Ltd. (\"Roivant\") for $100.00 per Preferred Share (the \"Purchase Price\"), which price is subject to increase to reflect the addition of any unpaid participating cash dividends and unpaid participating in-kind dividends."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Subject to earlier conversion at Roivant's option upon the occurrence of certain limited events set forth in the amendment to the Notice of Articles and the Articles of the Issuer (the \"Preferred Shares Articles Amendment\"), the Preferred Shares mandatorily convert on October 16, 2021, to the extent not already converted, into (i) unpaid accrued participating in-kind dividends and cash for any unpaid accrued cash dividends, as set forth in the Preferred Shares Article Amendment, and (ii) common shares of the Issuer, no par value (the \"Common Shares\"), which is determined by dividing (a) the Purchase Price, plus an amount equal to 8.75% of the Purchase Price per year, compounded annually, by (b) the conversion price in effect at the time of conversion. Each Preferred Share is initially convertible based on a conversion price of $7.13, subject to adjustment for certain distributions and other transactions by the Issuer on or with respect to the Common Shares."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Preferred Shares are directly beneficially owned by Roivant. Pursuant to Roivant's internal governance documents, following the appointment to Roivant's board of directors of one or more directors meeting certain independence criteria (each an \"Independent Director\" and collectively the \"Independent Directors\"), dispositions of the Preferred Shares require the approval of a majority of Roivant's board of directors, including (i) at least two Independent Directors, or, (ii) if there is only one Independent Director, that sole Independent Director. The reporting person is an Independent Director of Roivant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"As the approval of the reporting person as an Independent Director, and, to the extent one other Independent Director is serving, that other Independent Director, is needed for Roivant to dispose of the Preferred Shares, the reporting person may be deemed to have dispositive power over, and to be an indirect beneficial owner of, the Preferred Shares directly beneficially owned by Roivant. The reporting person disclaims beneficial ownership of the Preferred Shares owned by Roivant, except to the extent of his respective pecuniary interest therein. This filing shall not be deemed an admission that the reporting person and any other Independent Director constitute a \"group\" for purposes of Section 13(d) or Section 13(g) of the Securities Exchange Act of 1934, as amended."}],"balance_after":500000,"derivative":{"exercise_price":7.13,"expiration_date":"2021-10-16","underlying":"Common shares, no par value","underlying_shares":9808386},"source":{"system":"sec-edgar","filing":"0001104659-17-062445","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1447028/000110465917062445/a4.xml","form_type":"4"}}]}